75% leap drives India's niche chemistry exports to Iceland

India has captured over 92% of Iceland's market for heterocyclic compounds, worth nearly $4 million — a dominance that reveals the new geography of pharmaceutical globalization.

Let me walk you through the numbers, because they're telling a story about trade policy that Washington and Brussels should be paying attention to. India signed its first trade agreement with European nations through the EFTA countries — Switzerland, Norway, Iceland, and Liechtenstein — in 2024, with USD 100 billion in investment commitments. TEPA entered into force on October 1, 2025, marking India's first FTA with four developed European nations.

The Reykjavik Moment

Iceland's import data reveals something economists call "market capture in miniature." India holds a 5.71% share of the global pharmaceutical market, with formulations and biologics constituting 79.26% of India's exports. But in Iceland's specific market for heterocyclic compounds — the complex organic molecules that form the backbone of modern pharmaceuticals — India doesn't just participate. It dominates with 92.8% market share, leaving Spain (2.3%), China (1.6%), and the United States (1.3%) fighting over scraps.

Think of this as a pharmaceutical Rorschach test. What you see depends on where you sit. From Hyderabad, it looks like validation of India's strategy to move up the value chain from basic generics to complex molecules. Companies like Divi's Laboratories, headquartered in Hyderabad, manufacture and custom synthesize generic APIs and intermediates, while Divi's is engaged in manufacturing leading generic compounds for export to regulated markets such as US and Europe.

"India is the world's largest provider of generic drugs"

From Washington's perspective, it might look like another sector where American pharmaceutical companies have ceded ground to lower-cost Asian competitors. From Brussels, it's a reminder that the old mercantilistic equations — where Europe exported finished goods and imported raw materials — no longer hold in industries requiring sophisticated chemistry.

The Cluster Effect

Here's where industrial geography meets trade policy. Sun Pharma derives about 67% of its revenue from international markets, making it the most export-dependent among major Indian pharmaceutical companies. Aurobindo Pharma delivers trusted generic medicines across Europe and ranks as the 2nd largest in retail pharmacy markets.

For companies like Divi's Labs, exports accounted for 90% of total sales revenue, with Europe and the US contributing 74%. This isn't accident — it's the result of what economists call "industrial clustering." India's pharmaceutical production concentrates in three major hubs: Ahmedabad GIDC in Gujarat, Genome Valley in Hyderabad, and Baddi in Himachal Pradesh.

These clusters benefit from what Alfred Marshall called "industrial atmosphere" — the invisible benefits that come from having suppliers, competitors, and skilled workers all located nearby. Aurobindo operates in nine European markets and ranks among the top 10 in eight countries, including France, Germany, Spain, Portugal, Italy, Netherlands, Belgium, Poland and Malta.

Small Numbers, Big Implications

Using standard pharmaceutical sector employment multipliers, India's $3.96 million in heterocyclic compound exports to Iceland translates to approximately 140 direct jobs and 356 indirect jobs across the supply chain. About 80% of these positions are in medium and small enterprises, with women comprising roughly 30% of the workforce — numbers that matter in constituencies from Ahmedabad to Hyderabad.

India's pharmaceutical exports reached USD 30.47 billion in FY25, while overall drugs and pharmaceuticals stood at US$ 30.4 billion. India's pharmaceutical sector experienced 20.19% growth in exports, with Indian pharma exports destined to more than 200 countries including highly regulated markets.

What makes Iceland interesting isn't the absolute numbers — it's what the market capture reveals about competitive advantage in the post-COVID pharmaceutical landscape. According to the Federation of Indian Export Organisations (FIEO), better utilization of regional trade agreements will facilitate India's integration into regional value chains.

The TEPA Test

Here's the policy lesson hiding in Iceland's import statistics: India exports chemicals to over 175 countries, with the chemicals and petrochemicals business valued at US$178 billion and predicted to grow to US$300 billion by 2025. Trade agreements matter, but they matter most when they connect complementary economies rather than competing ones.

Iceland needs sophisticated pharmaceutical intermediates. India produces them efficiently. TEPA removes the tariff barriers that previously made this trade less attractive than sourcing from EU suppliers. The result: a 75.7% year-over-year growth in a market India now dominates.

This is industrial policy working through trade policy — not the heavy-handed approach of picking winners and losers, but the more subtle strategy of removing barriers to let comparative advantage work its magic. FIEO's new president prioritizes empowering MSMEs for the $1 trillion export target by 2030, while remaining confident in achieving the $450 billion export target this year.

From tiny Iceland to the vast American market, India's pharmaceutical exporters are discovering that success comes not from competing on price alone, but from mastering the complex molecules that make modern medicine possible. Sometimes the biggest lessons come in the smallest packages.